EP1287362A4 - Zusammensetzungen und verfahren zur modulation tumorspezifischer expression - Google Patents

Zusammensetzungen und verfahren zur modulation tumorspezifischer expression

Info

Publication number
EP1287362A4
EP1287362A4 EP01945989A EP01945989A EP1287362A4 EP 1287362 A4 EP1287362 A4 EP 1287362A4 EP 01945989 A EP01945989 A EP 01945989A EP 01945989 A EP01945989 A EP 01945989A EP 1287362 A4 EP1287362 A4 EP 1287362A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
specific expression
tumor specific
modulating tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01945989A
Other languages
English (en)
French (fr)
Other versions
EP1287362A2 (de
Inventor
Thomas A Gardner
Chinghai Kao
Song-Chu Ko
Fan Yeung
Leland W K Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of Virginia
Original Assignee
University of Virginia
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia, University of Virginia Patent Foundation filed Critical University of Virginia
Publication of EP1287362A2 publication Critical patent/EP1287362A2/de
Publication of EP1287362A4 publication Critical patent/EP1287362A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP01945989A 2000-05-25 2001-05-24 Zusammensetzungen und verfahren zur modulation tumorspezifischer expression Withdrawn EP1287362A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20790000P 2000-05-25 2000-05-25
US207900P 2000-05-25
PCT/US2001/016944 WO2001090306A2 (en) 2000-05-25 2001-05-24 Compositions and methods for modulating tumor specific expression

Publications (2)

Publication Number Publication Date
EP1287362A2 EP1287362A2 (de) 2003-03-05
EP1287362A4 true EP1287362A4 (de) 2004-05-12

Family

ID=22772429

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01945989A Withdrawn EP1287362A4 (de) 2000-05-25 2001-05-24 Zusammensetzungen und verfahren zur modulation tumorspezifischer expression

Country Status (6)

Country Link
EP (1) EP1287362A4 (de)
JP (1) JP2004510406A (de)
CN (1) CN1447920A (de)
AU (1) AU2001268087A1 (de)
CA (1) CA2410094A1 (de)
WO (1) WO2001090306A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015277369B2 (en) * 2014-06-16 2021-08-19 The Johns Hopkins University Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶
CA3144637A1 (en) * 2019-06-21 2020-12-24 Kernal Biologics, Inc. Engineered oncoselective protein expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides

Also Published As

Publication number Publication date
WO2001090306A3 (en) 2002-04-04
CN1447920A (zh) 2003-10-08
AU2001268087A1 (en) 2001-12-03
WO2001090306A2 (en) 2001-11-29
JP2004510406A (ja) 2004-04-08
CA2410094A1 (en) 2001-11-29
EP1287362A2 (de) 2003-03-05

Similar Documents

Publication Publication Date Title
EP1539218A4 (de) ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULIERUNG DER LYMPHOZYTENAKTIVITûT
ATE411332T1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
ID28965A (id) Azabisikloalkana sebagai modulator ccr5
GB2341955B (en) Web walker emulator
FR2768916B1 (fr) Agrafe d'osteotomie tibiale
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
EP1061800A4 (de) Zusammensetzungen und verfahren zur modulierung der vaskularisation
DE59808818D1 (de) Chirurgischer Spreizer
EP1572944A4 (de) Verfahren und zusammensetzungen zur modulation der aktivität von xbp-1
DE69834019D1 (de) Dose
DE69902473D1 (de) Kosmetikzusammensetzung
NO20023837L (no) Modulering av bendannelse
EP1709206A4 (de) Zusammensetzungen und verfahren zum modulieren der sirtuin-aktivität
FR2796829B1 (fr) Plaque d'osteotomie tibiale
FR2817502B1 (fr) Materiau d'operculage pelable et refermable
EP1314428A4 (de) Oct-zubereitungen
DE69801242D1 (de) Düngerstreuer
EP1261346A4 (de) REGULIERUNG EINER KARDIOVASKULäREN VERLETZUNG
FR2812695B1 (fr) Disque d'embrayage
FR2812697B1 (fr) Disque d'embrayage
AU2001268087A1 (en) Compositions and methods for modulating tumor specific expression
DE69931423D1 (de) BPSK-Modulator
EP1631235A4 (de) Zusammensetzungen und verfahren zur modulation der expression von b7 protein
UA3151S (uk) Етикетка для чаю "сер джонс"
KR970016232U (ko) 신발 살균 악취 제거기

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021218

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040326

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/47 B

Ipc: 7A 61K 48/00 B

Ipc: 7G 01N 33/567 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040504